secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2023-10-27T23:59:59+00:00
Accession:  0000950170-23-055985
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Kezar Life Sciences enters separation agreement with former CMO Noreen Roth Henig
--------------------------------------------------------------------------------

- Dr. Henig stepped down as CMO effective Oct 6, 2023; separation agreement signed Oct 23, 2023.
- Cash severance: 12 months base salary plus 40% of target bonus, paid over 12 months.
- Reimbursement of up to 12 months of COBRA premiums; vested stock option exercise extended to Dec 31, 2024.
- Severance contingent on a general release of claims effective Oct 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000095017023055985/0000950170-23-055985-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000095017023055985/kzr-20231023.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-055985

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer